|
Volumn 19, Issue 56, 2000, Pages 6566-6573
|
Design of growth factor antagonists with antiangiogenic and antitumor properties
a b |
Author keywords
Angiogenesis; Cancer drug discovery; Oncogenesis; Platelet derived growth factor
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
GFB 105;
GFB 106;
GFB 107;
GFB 108;
GFB 109;
GFB 110;
GFB 111;
GFB 112;
GFB 113;
GFB 115;
GFB 116;
GFB 117;
GFB 119;
GFB 120;
GFB 122;
GROWTH FACTOR BINDING INHIBITOR;
PLATELET DERIVED GROWTH FACTOR INHIBITOR;
PLATELET DERIVED GROWTH FACTOR RECEPTOR;
UNCLASSIFIED DRUG;
ANTINEOPLASTIC ACTIVITY;
CANCER INHIBITION;
DRUG DESIGN;
DRUG RECEPTOR BINDING;
DRUG STRUCTURE;
HUMAN;
PRIORITY JOURNAL;
REVIEW;
SIGNAL TRANSDUCTION;
ANGIOGENESIS INHIBITORS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CELL DIVISION;
DRUG DESIGN;
MICE;
MICE, NUDE;
MODELS, MOLECULAR;
PEPTIDES, CYCLIC;
PROTEIN BINDING;
RECEPTOR PROTEIN-TYROSINE KINASES;
RECEPTORS, PLATELET-DERIVED GROWTH FACTOR;
SIGNAL TRANSDUCTION;
MUS MUSCULUS;
|
EID: 0034722887
PISSN: 09509232
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.onc.1204121 Document Type: Review |
Times cited : (51)
|
References (27)
|